Canada: Companion Diagnostics – A Patented Drug's Best Friend

Intellectual property strategy is fundamental to the successful development and commercialization of a personalized therapeutic and its companion diagnostic. In personalized therapy, healthcare professionals often use genetically-guided diagnostic tests to identify which medical treatments will be the safest and most effective for each patient. As the pharmaceutical industry transitions from the age of one-size-fits-all drugs to the age of personalized therapeutics, companion diagnostics will become indispensable in disease treatment and prevention. According to the Personalized Medicine Coalition, new personalized therapeutic drugs approved by the FDA are on an upward trajectory. They have risen from about 5% of all new drugs in 2005 to over 25% in 2015 and 2016.

The era of personalized therapeutics is highlighted by the success of Merck's Keytruda (pembrolizumab), a humanized antibody used in cancer immunotherapy which targets the programmed cell death 1 (PD-1) receptor. Keytruda was initially approved for the treatment of unresectable or metastatic melanoma as a second-line therapy. Dako, in partnership with Merck, developed "PD-L1 IHC 22C3 pharmDx." This is a companion diagnostic that detects the level of programmed death-ligand 1 (PD-L1) protein, a binding partner of PD-1. With the aid of this companion diagnostic, clinical trials were carried out to find and treat patients who are most likely to benefit from Keytruda, i.e. patients who have high expression level of PD-L1 proteins on their tumor tissues. This targeted strategy has realized its goals, by helping the drug obtain its approval. In October 2015, the FDA approved expanding the indication for Keytruda for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents. In October 2016, Keytruda was approved as a first-line treatment for metastatic NSCLC in patients with high-levels of PD-L1. In the U.S., Keytruda is protected by U.S. Patents 8,354,509 and 8,900,587 which disclose the therapeutic PD-1 specific antibody and its pharmaceutical composition.

While most companion diagnostics are used in conjunction with one particular therapeutic drug, others are more versatile. They can help select an effective treatment from a range of options, based on the results of the test and the patient's treatment history. A case in point is "cobas EGFR Mutation Test v2" developed by Roche, which is a companion diagnostic test for Tarceva (erlotinib) and Tagrisso (osimertinib), both of which are small molecule EGFR inhibitors used for NSCLC treatment. Tarceva is marketed in the U.S. by OSI Pharmaceuticals and Genentech (a subsidiary of Roche), whereas Tagrisso is marketed in the U.S. by AstraZeneca. The diagnostic uses a real-time PCR test. If the tested tumor tissue from a patient was determined to harbor exon 19 deletions and L858R mutation in EGFR, then the patient is most likely to benefit from Tarceva as a first-line treatment. If the EGFR was determined to have the mutation T790M, then the patient is most likely to benefit from Tagrisso in second and subsequent lines of therapy. In the U.S., Tarceva is protected by U.S. Patents 5,747,498, 6,900,221, 7,087,613, and RE41065, which cover the molecule, its pharmaceutical use and methods of production. Tagrisso is protected by U.S. Patent 8,946,235, which discloses the molecule, its pharmaceutical composition, and method for treatment related to the molecule. The cobas EGFR Mutation Test v2 itself is protected by U.S. Patent 7,687,247 related to the reaction mixture and DNA amplification composition, and U.S. Patent 7,964,349 that claims for a method for determining pharmacological effectiveness of treatment by erlotinib. The 7,964,349 patent is licensed to Roche by the General Hospital Corp and the Dana-Farber Cancer Institute. This is an example of how academically-driven inventions protected by patents are valued by industry and play a role in the development and commercialization of personalized medicine.

In another example, Venetoclax (Venclexta) is a small molecule oral treatment for chronic lymphocytic leukemia (CLL) marketed by Abbvie and Genentech in the U.S. This drug was granted "Breakthrough Therapy Designation" and later received accelerated FDA approval for CLL patients who have been refractory to previous treatment and have chromosomal deletion at Locus Specific Identifier (LSI) TP53. Venetoclax is linked to U.S. Patents 8,546,399 and 9,174,982 which claim the small molecule and the method of cancer treatment with the small molecule. The companion diagnostic for Venetoclax is the "Vysis CLL FISH Probe Kit" manufactured by Abbott Molecular which detects the deletion of LSI TP53 in blood specimens from patients. In addition to its prescribed use for detecting LSI TP53 deletion as an aid in identifying those patients with CLL who might benefit with Venetoclax treatment, the kit could also detect deletion of LSI ATM and LSI D13S319, and gain of the D12Z3 sequence. These additional features provide the potential for expanded use in the future. The direct-label fluorescence probes in the kit are covered by U.S. Patents 6,607,877, 7,115,709 and RE40,494, which are exclusively licensed to Abbott Molecular by The Regents of the University of California. The methods utilized by the kit in detecting multiple hybridization signals simultaneously are covered by U.S. Patent 6,203,977. This patent is exclusively licensed to Abbott Molecular by Yale University.

The rapid pace of personalized medicine development will gain momentum with advances in chemogenomics, high-throughput production of interactome data, and the coming of age of next-generation sequencing technologies. This trend is not lost on the FDA. The agency has recently provided draft guidance on the "Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product". The diagnostic is regulated as a medical device. Competition in this space will intensify, so intellectual property protection strategies are key to support company commercialization, as well as opening up collaborative and licensing opportunities for academic institutions. In all, bringing safe and effective personalized medicine to the market serves the ultimate goal of matching the right drug with the right patient in need.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Herman H. Cheung
In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.